Form 4: Regeneron EVP Neil Stahl Reports Stock Gift and Beneficial Ownership Changes
SEC Form 4 Filing
Neil Stahl, EVP of Research and Development at Regeneron Pharmaceuticals, reported a gift of 1,020 shares of common stock and changes in beneficial ownership, including holdings in a 401(k) plan and spousal trust.
Summary
- On February 26, 2024, Neil Stahl, the Executive Vice President of Research and Development at Regeneron Pharmaceuticals, reported a transaction involving the company's common stock.
- Mr. Stahl gifted 1,020 shares of Regeneron common stock.
- Following the transaction, Mr. Stahl directly owns 50,999 shares of Regeneron common stock.
- Additionally, Mr. Stahl indirectly owns 5,834 shares through a 401(k) plan and 4,605 shares through a spousal trust.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, reporting stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive stock transactions and beneficial ownership, common for publicly traded companies like Regeneron.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in ownership, but it's unlikely to be significant.
Key Dates
| Date | Description |
|---|---|
| 02/26/2024 | Date of stock gift transaction |
| 02/27/2024 | Date of signature on the Form 4 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.